Skip to main content

Table 2 Utility weights used for quality-adjusted life-years in the decision tree analysis

From: Cost-effectiveness analysis of neoadjuvant versus adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer patients during initial treatment phase

  Utility weight Time frame (months) Source
Surgery + chemotherapy 0.81 4.87 Dendulur et al. [22]
Grutters et al. [23]
≥ 3 grade AE 0.45 0.73
≥ 3 grade complication 0.63 0.50 Handorf et al. [25]
Lugg et al. [26]
Surgery alone 0.77 0.53 Dendulur et al. [22]
Grutters et al. [23]
Chemotherapy alone 1.00 0.21
Death 0